Holen Sie sich die Stockscreener-App
64.67
1.12%
-0.73
Vorhandelsmarkt:
64.50
-0.17
-0.26%
Mirum Pharmaceuticals Inc Aktie (MIRM) Neueste Nachrichten
Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The AI Journal
Mirum Pharmaceuticals stock price target raised to $100 by Leerink - Investing.com UK
Trading Systems Reacting to (MIRM) Volatility - news.stocktradersdaily.com
Baird Maintains Mirum Pharmaceuticals (MIRM) Outperform Recommendation - Nasdaq
Mirum adds to liver disease pipeline with Bluejay takeout: Deals Report - BioCentury
Peninsula companies to merge in potential $820M deal centered around a drug that was cast off by Novartis - The Business Journals
Mirum Pharmaceuticals' Bluejay Acquisition Expands Liver Disease Pipeline, Morgan Stanley Says - marketscreener.com
Mirum Pharmaceuticals price target raised to $130 from $95 at Cantor Fitzgerald - Yahoo Finance
Mirum to buy Bluejay for up to $820m in rare liver disease push - Yahoo Finance
Mirum Pharmaceuticals stock rises as H.C. Wainwright reiterates Buy rating By Investing.com - Investing.com UK
Morgan Stanley Raises Price Target on Mirum Pharmaceuticals to $95 From $81, Keeps Overweight Rating - marketscreener.com
Mirum Pharmaceuticals, Inc. $MIRM Shares Purchased by Jump Financial LLC - MarketBeat
Mirum Pharmaceuticals Enters into Definitive Agreement to Acquire Bluejay Therapeutics, Expanding Global Leadership in Rare Disease - BioSpace
Five things for pharma marketers to know for Tuesday, December 9, 2025 - Medical Marketing and Media
Baird raises Mirum Pharmaceuticals stock price target to $88 on Bluejay acquisition - Investing.com Canada
Mirum Pharma to buy Bluejay Therapeutics for up to $820 million - WTVB
Mirum Adds To Rare Liver Disease Portfolio With Bluejay Acquisition - Citeline News & Insights
Mirum Pharmaceuticals stock rises as Morgan Stanley reiterates Overweight rating - Investing.com Canada
Mirum Pharmaceuticals, Inc. (MIRM) Bluejay Therapeutics, Inc.,M&A CallSlideshow (NASDAQ:MIRM) 2025-12-08 - Seeking Alpha
MIRM: Acquisition brings a breakthrough hepatitis delta therapy, expanding rare disease leadership - TradingView
Mirum gains a hepatitis D drug in $620M buyout of startup Bluejay - BioPharma Dive
Mirum Pharmaceuticals, Inc. entered into a definitive agreement to acquire Bluejay Therapeutics, Inc for $820 million. - marketscreener.com
Mirum Stock Slips On $820M Bluejay Deal — But Wall Street Calls The Hepatitis Drug Seal A 'Steal' - MSN
Latham & Watkins Advises Bluejay Therapeutics in US$620 Million+ Acquisition by Mirum Pharmaceuticals - Latham & Watkins LLP
Mirum expands into liver diseases with Bluejay Therapeutics acquisition - Seeking Alpha
Mirum Pharma to buy Bluejay Therapeutics for up to $820M - Axios
Mirum Pharmaceuticals Enters into Definitive Agreement to Acquire Bluejay Therapeutics, Expanding Gl - pharmiweb.com
Mirum Pharmaceuticals To Acquire Bluejay Therapeutics In Rare Liver Disease Expansion - Nasdaq
Mirum to buy Bluejay for up to $820 million in bet on liver-disease drug - marketscreener.com
Mirum Pharmaceuticals to Acquire Bluejay Therapeutics - Contract Pharma
Mirum Pharmaceuticals to acquire HBM portfolio company Bluejay Therapeutics - marketscreener.com
Mirum Pharmaceuticals to acquire HBM portfolio company Bluejay Therapeutics for up to USD 820 million - TradingView
Mirum to acquire Bluejay for $620 million, adding HDV treatment - Investing.com
Mirum Pharmaceuticals enters into definitive agreement to acquire Bluejay Therapeutics - marketscreener.com
Mirum to acquire Bluejay for $620 million, adding HDV treatment By Investing.com - Investing.com South Africa
Mirum Pharmaceuticals (NASDAQ: MIRM) to acquire Bluejay Therapeutics, adds HDV drug brelovitug and $200M PIPE - Stock Titan
Mirum Pharmaceuticals (MIRM) up 1.3% since last earnings report: Can it continue? - MSN
Affinity Asset Advisors LLC Cuts Holdings in Mirum Pharmaceuticals, Inc. $MIRM - MarketBeat
MIRM SEC FilingsMirum Pharmaceuticals 10-K, 10-Q, 8-K Forms - Stock Titan
How geopolitical risks impact Mirum Pharmaceuticals Inc. (08D) stockWeekly Earnings Recap & AI Driven Stock Price Forecasts - Newser
How Mirum Pharmaceuticals Inc. (08D) stock responds to job market shiftsJuly 2025 Trends & Consistent Profit Trade Alerts - Newser
Stronger 2025 Outlook And Fragile X Trial Start Might Change The Case For Investing In Mirum (MIRM) - Yahoo Finance
Is Mirum Pharmaceuticals Inc. (08D) stock worth buying before Fed action2025 Market Sentiment & Daily Market Momentum Tracking - Newser
Mirum Pharmaceuticals (MIRM) Up 1.3% Since Last Earnings Report: Can It Continue? - Yahoo Finance
JPMorgan Chase & Co. Purchases 192,340 Shares of Mirum Pharmaceuticals, Inc. $MIRM - MarketBeat
Mirum Pharmaceuticals, Inc. $MIRM Position Boosted by Russell Investments Group Ltd. - MarketBeat
Prediction: This Stock Has Soared Nearly 70% in 2025 and Will Be an Even Bigger Winner in 2026 - Yahoo Finance
Will Mirum Pharmaceuticals Inc. stock continue upward momentumWeekly Trade Report & Verified Stock Trade Ideas - Newser
Mirum Pharmaceuticals Insider Sold Shares Worth $3,700,000, According to a Recent SEC Filing - marketscreener.com
Mirum Pharmaceuticals Director Sells 50,000 Shares - TradingView
Mirum Pharmaceuticals(MIRM.US) Director Sells US$3.7 Million in Common Stock - 富途牛牛
Mirum Pharmaceuticals (MIRM) Stock Analysis Report | Ratings, Financials & Performance - Benzinga
MIRM Enrolls First Patient in Phase II Fragile X Syndrome Study - sharewise.com
Will Mirum Pharmaceuticals Inc. (08D) stock gain from green policiesEarnings Performance Report & Precise Swing Trade Entry Alerts - Newser
Mirum enrolls first patient in Fragile X syndrome oral therapy study - Investing.com Canada
Mirum enrolls first patient in Fragile X syndrome oral therapy study By Investing.com - Investing.com South Africa
0.45%
0.12%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):